Charles River Acquires Accugenix
Expands Microbial Identification Capabilities
WILMINGTON, Mass.--(BUSINESS WIRE)--Aug. 29, 2012-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Accugenix, Inc., the premier global provider of cGMP-compliant contract microbial identification testing, for approximately $17 million in cash. This acquisition strengthens Charles River's Endotoxin and Microbial Detection1 (EMD) portfolio of products and services by providing clients with state-of-the-art microbial detection services for manufacturing in the biopharmaceutical, medical device, nutraceutical and consumer care industries. The acquisition is expected to be neutral to earnings per share on both a GAAP and non-GAAP basis in 2012. In 2013, it is expected to represent approximately 1% of total net sales and be slightly accretive to both GAAP and non-GAAP earnings per share.
Accugenix is an acknowledged industry leader in species-level identification and strain typing of bacteria and fungi that are recovered from manufacturing facilities. The company has invested in proprietary library databases which allow it to identify over 5,000 species of organisms. Utilizing state-of-the-art and proprietary in vitro technologies, coupled with scientific expertise and analysis, Accugenix excels in providing accurate, time-effective and cost-effective microbial identification services required to meet internal quality standards and government regulations.
James C. Foster, Chairman, President and Chief Executive Officer of Charles River said, "The acquisition of Accugenix is the first step in our broader strategy to become the premier provider of rapid microbial and endotoxin detection products and services to the biopharmaceutical industry. Over the next several years, we intend to enhance our capabilities through both product extensions and acquisitions. We believe that execution of this strategy will advance our position as the market leader in endotoxin and microbial detection."
Caution Concerning Forward-Looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements include statements in this press release regarding the acquisition of Accugenix, Inc., and Charles River's expectations with respect to the impact of Accugenix on the Company, its service offerings, net sales and earnings, as well as Charles River's future growth in the area of endotoxin and microbial detection. Forward-looking statements are based on Charles River's current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to, the ability to successfully consummate the acquisition of Accugenix. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 27, 2012, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this news release except as required by law.
About Charles River
Accelerating Drug Development. Exactly. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit http://www.criver.com.
1 Charles River's Endotoxin and Microbial Detection business is also referred to as "Endosafe" or "In Vitro."
Source: Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc.Investor Contact:Susan E. Hardy, 781-222-6190Corporate Vice President, Investor RelationsorMedia Contact:Amy Cianciaruso, 781-222-6168Associate Director, Public Relations
For more information, contact us at:
*indicates a required field.
The information you provided will be kept confidential.
Our newest Accugenix® tech note provides insight into the various methods of fungal identification and their limitations. The need to establish an environmental monitoring program with access to a relevant and accurate microbial reference library is also discussed.
Virus filters are used in biomanufacturing to ensure the safety of biopharmaceutical drug products. As part of filter implementation, manufacturers are required to validate that the filtration process can indeed remove the virus. This article highlights areas to be explored during process development before the validation study to ensure that potential artifacts do not negate the scaled-down model.
Jun 21–Jun 25
This five-day meeting draws diverse professionals from around the world to share their breakthroughs in the prevention, diagnosis and treatment of diabetes.
Sep 12–Sep 13
Standard Operating Procedures (SOPs) are an integral part of a successful quality system as they provide individuals with the information to perform a job properly and facilitate consistency in the quality and integrity of a product or end result.
Jun 28–Jun 28
Charles River offers a wide range of seminars, workshops and training courses for animal technicians, veterinarians, biologists and laboratory technicians who work with laboratory animals. For more information about our course on animal health monitoring, click "view more" below.
This position is responsible for managing international aspects of US Federal income tax compliance; assisting with international tax planning, including identification of planning opportunities, designing and implementing plans, and transfer pricing process; overseeing quarterly ETR forecast process; and participating in the tax provision process, including assessment of tax risks, documentation of key positions, and review of non-US tax provision submissions.
This position is responsible for serving as a as a study director (SD), project scientist (PS) and/or principal investigator (PI) in the direction and execution of assigned studies in compliance with GLP regulations as they apply to the conduct of nonclinical research; coordinating all phases of the study planning process with appropriate departments; generating high-quality project plans, protocols, amendments and reports appropriate for assigned studies; reviewing, interpreting, integrating and presenting data on assigned studies; and functioning as contact for the planning and execution of sponsor interaction related to assigned studies, including proposal management and study scheduling, conduct and reporting.
Charles River Laboratories, Inc.